Axonics (NASDAQ:AXNX) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Axonics (NASDAQ:AXNX) in a research note issued to investors on Friday morning,Benzinga reports.

Axonics Price Performance

Shares of NASDAQ:AXNX opened at $70.48 on Friday. The company’s fifty day moving average price is $69.73 and its 200-day moving average price is $68.49. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of -587.28 and a beta of 0.82. Axonics has a one year low of $50.55 and a one year high of $70.75.

Insider Activity at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.85% of the stock is owned by insiders.

Institutional Investors Weigh In On Axonics

Large investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new stake in shares of Axonics in the 1st quarter worth about $218,000. Swiss National Bank lifted its position in shares of Axonics by 0.6% in the 1st quarter. Swiss National Bank now owns 100,000 shares of the company’s stock worth $6,897,000 after purchasing an additional 600 shares during the period. Headlands Technologies LLC lifted its position in shares of Axonics by 31.1% in the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after purchasing an additional 265 shares during the period. QRG Capital Management Inc. purchased a new stake in shares of Axonics in the 1st quarter worth about $828,000. Finally, ProShare Advisors LLC lifted its position in shares of Axonics by 54.9% in the 1st quarter. ProShare Advisors LLC now owns 12,752 shares of the company’s stock worth $880,000 after purchasing an additional 4,517 shares during the period. Institutional investors own 99.48% of the company’s stock.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.